




BIOEUROPE SPRING 2020

Paris, 23-25 mars 2020

STAND 85



Wallonia.be

EXPORT
INVESTMENT

BIOEUROPE SPRING 2020

Paris, 23-25/03/2020

Stand 85




WALLONIA EXPORT-INVESTMENT AGENCY

Place Saintelette, 2
B - 1080 Brussels
Phone: + 32 2 421 82 11
E-mail: info@awex.be
Website: www.awex.be

Martine LECLERCQ, Economic and Commercial Counselor
Représentation Wallonie-Bruxelles
274, boulevard Saint Germain
75007 Paris
T 33-1-53.85.05.30
E-mail : paris@awex-wallonia.com

Catherine LHEUREUX, Investment Development Manager -
France
T +32 (0)81 33 28 57
E-mail : clheureux@investinwallonia.be

Laurent RENSON, Project Manager
T 32-2-421.86.93
E-mail : l.renson@awex.be



Wallonia.be

EXPORT
INVESTMENT

The Wallonia Export-Investment Agency (AWEX) is the institution in charge of the development and management of Wallonia's domestic and international economic relations.

Through a personalized, innovative, and sustainable approach, AWEX supports Walloon companies - regardless of their size, sector, or target market - in every step of their international endeavors. This includes exports, technological partnerships, and development abroad.

The agency's vast network of connections ensures the best advisors are always by your side. Our local anchors and agents abroad are capable of providing unparalleled insight to take your company to the next level. In addition, our connections will help establish your business in the global marketplace and promote it throughout the world. Training, incentives, and international financing are also available.

AWEX is also committed to strengthening Wallonia's position as the premier gateway for international investors seeking success in the heart of Europe. We work closely with them to inform, convince, and advise in every stage of their development.

Feel free to get in touch with one of our local or international agents via our websites listed above. In our network of more than 400 employees in nearly 100 countries around the world, there is always someone ready and willing to support you in your approach.

BIOWIN

Rue Auguste Piccard 20
6041 GOSSELIES
+ 32 (0) 71 91 92 85
contact@biowin.org
www.biowin.org

Marc Dechamps, Director International Affairs
marc.dechamps@biowin.org



BIOWIN FEDERATE INDUSTRIAL AND ACADEMIC PLAYERS (2018)

- 8 global leaders (Baxter, GSK, IBA, IRE, Janssen Pharmaceutica, Kaneka-Eurogentec, UCB, and Zoetis)
- 196 small and medium size companies
- 5 private research centers
- 5 Universities: UCL, ULB, ULiège, UMONS and UNamur (fitted with 400 research units, 11,000 researchers and 3 university hospitals)
- Prestigious research institutes such as the De Duve Institute, Ludwig Institute for Cancer Research, GIGA, IMI, etc.

KEY TECHNOLOGICAL AREAS SUPPORTED BY BIOWIN

- (Bio)pharmacy
- Cell Therapy
- Radiation applied to health
- Medical devices and in vitro diagnostics
- Bio manufacturing
- Data science

THE HEALTH SECTOR IN WALLONIA KEY FACTS & FIGURES (2018)

- 20,000 hospital beds
- European leader in clinical trial phase I
- EUR 1.2 billion private R&D expenses
- > EUR 2 billion cumulated private capital raised by BioWin SMEs Members (2005-2019)
- 22,525 direct jobs spread on 196 industrial BioWin members
- Favorable tax environment and R&D incentives
- A unique logistic location at the very heart of Europe

WALLONIA-BRUSSELS INTERNATIONAL

Délégation générale Wallonie-Bruxelles à Paris
274, Bd Saint-Germain
75007 Paris
Tel : 01 53 85 05 10
E-mail : delgen@walbru.fr
Website : <http://www.wbi.be/>

DELEGATE

BAMPINI Giacomo, Attaché Politique et Scientifique
Direct line : 01 53 85 05 36
E-mail : g.bampini@walbru.fr



COMPANY BACKGROUND

Wallonia-Brussels International (WBI) is the public body in charge of the international relations of Wallonia-Brussels. The Research & Innovation Unit aims to foster contacts and to build partnerships between research and innovation actors of Wallonia-Brussels and other countries.

ADDED VALUE

We create and build up international science, technology and innovation networks in an open innovation approach :

- academia : the universities and higher education institutions, their Technology Transfer Offices (LIEU), the funding agency for fundamental research (FNRS)
- business : the clusters and competitiveness clusters, the association of science parks of Wallonia (SPoW), the association of 20 applied research centers of Wallonia (Wal- Tech), the National Contact Point for Horizon Europe (NCP-Wallonie)
- public bodies : Sowalfin, Ministry of Economy & Research (SPW Recherche), the Walloon Trade & Investment Agency (AWEX)

RANGE OF PRODUCTS

What do we do ?

- connect scientists, researchers, entrepreneurs with inspiring partners of excellence ;
- facilitate academic programs, global innovation strategies and knowledge exchange ;
- support internationalization efforts of Wallonia-Brussels academic institutions and companies, with a special focus on innovative start-ups and spin-offs ;
- inform on developments in science.

CO-EXHIBITORS	Page
AEPODIA	7
ARTIALIS	8
BONE THERAPEUTICS	9
CSM	10
EUROGENTEC	11
IDDI	12
IMCYSE	13
IMMUNXPPTS	14
LIEU NETWORK	15
POLYPEPTIDE	16
PROMETHERA	17
SALAMANDERU	18
SAMBREINVEST	19
SECOYA	20
SPECTRALYS	21
SYNGULON	22
ULB	23
UNIVERCELLS	24
WBC VENTURES	25

CO-EXHIBITORS BY SECTORS

BIO-PHARMA - PRODUCTION

SECOYA

BIOTECHNOLOGY - THERAPEUTICS

BONE THERAPEUTICS

EUROGENTEC

IMCYSE

PROMETHERA BIOSCIENCES

SALAMANDERU

ULB

UNIVERCELLS

BIOTECH R&D (CRO - CDMO)

ARTIALIS

EUROGENTEC

IMMUNXPERS

LIEU NETWORK

PROMETHERA BIOSCIENCES

SPECTRALYS

BIOTECHNOLOGY - OTHERS

SYNGULON

DIAGNOSTICS

UNIVERCELLS

FINANCE

SAMBREINVEST

PUBLIC ORGANISATIONS

LIEU NETWORK

SERVICES - CONSULTANCY

AEPODIA

CSM

IDDI

IMMUNXPERS

SALAMANDERU

WBC VENTURES

PHARMA

ULB

AEPODIA

Rue Louis de Geer, 6
1348 LOUVAIN-LA-NEUVE

Tel.: +32 10 39 20 11
E-mail: info@aepodia.com
Website: www.aepodia.com

DELEGATE

Denis GOSSEN, Chief Scientific Officer & co-Founder
Direct line : +32 10 39 20 07
Mobile : +32 485 66 53 40
E-mail : denis.gossen@aepodia.com



COMPANY BACKGROUND

Experts in the early development of drugs and medical devices up to clinical proof-of-concept (from preclinical to Phase 2). Via its network of partners, Aepodia facilitates access to patients and to validated clinical centres throughout Europe. With offices in Belgium and France, Aepodia is a recognized partner for pharmaceutical and biotechnology companies since 2007.

ADDED VALUE

Optimize drug development plan of potential lead candidates up to early clinical stage,
Optimized approaches for the conduct of early clinical studies (adaptive designs, biomarkers, ongoing adjustments and continual reassessment,...),
Definition of overall development plan (formulation, preclinical and clinical activities) including Go/No Go decisions and Critical Success Factors,
Delivery of robust clinical data to increase the value of the asset.

RANGE OF PRODUCTS

Due Diligence and Drug Development Advice (from lead identification to clinical Phase 2),
Prepare and review regulatory documents to enable First administration in Human (FIH),
Set-up and manage clinical studies (Phase I to II, proof-of-concept (POC)) in various Therapeutic Areas,
Clinical sites identification, study feasibility, assessments and qualification according to GMP, GLP and GCP (primarily in EU region).

MAIN REFERENCES

Spin-out of Eli Lilly - Established Partnership with mid-size Pharma (e.g. Ipsen) - Collaborate with various Biotech companies established in EU and in the USA.

CERTIFICATION

Execution of Services according to ICH E6 (GCP) and GCLP; Multiple and Regular Audits by Clients. Quality Management Systems (QMS); Help Biotech to develop their own QMS and appropriate set of SOPs.

ARTIALIS SA

Avenue de l'Hôpital, 11
GIGA B34 +3
4000 LIEGE

Tel : +32 42 42 77 27
E-mail: bd@artialis.com
Website: www.artialis.com

DELEGATE

Christelle BOILEAU, Chief Business Officer
Mobile: +32 474 82 77 22
E-mail: christelle.boileau@artialis.com



COMPANY BACKGROUND

Integrating scientific expertise and support for research, Artialis is your specialized partner for product development in rheumatology and musculoskeletal diseases from preclinical studies (in vitro and in vivo) to clinical trials.

ADDED VALUE

Artialis is able to work all the path of product development from preclinical studies to clinical trials (Phase 1 to 4) to address unmet needs. Artialis is partner of choice for the development of therapeutic approaches (drug, medical device as well as food supplement) for biotech, pharma companies and food supplement/nutrition industry.

RANGE OF PRODUCTS

Preclinical services:

In vitro and In vivo tailor made efficacy studies - PD/PK - Imaging - Ex vivo testing (Histology, Biomarkers & Biomechanics)

Clinical services:

Trial design and management (first-in-man to phase IV) - Protocol writing - KOL & Scientific board - Innovative markers - Site selection & management - Recruitment tools - Data monitoring - Data management & Biostatistics - Final report - Scientific Writing

Biotesting:

Imaging and soluble biomarkers centralized platform

CERTIFICATION

ISO9001, GCP, GCLP

BONE THERAPEUTICS

Rue Auguste Piccard, 37
6041 GOSSELIES

Tel.: +32 2 529 59 90
E-mail : info@bonetherapeutics.com
Website : www.bonetherapeutics.com

DELEGATE

Ching Man CHOI, Business Development Manager
E-mail: chingman.choi@bonetherapeutics.com



COMPANY BACKGROUND

Bone Therapeutics is a clinical-stage orthopaedic biotech company committed to rebuilding lives of patients suffering from debilitating bone and joint conditions.

ADDED VALUE

Leveraging its decade-long expertise in bone physiology and patented manufacturing technology, Bone Therapeutics' unique allogeneic bone cell therapy platform, ALLOB, and its off-the-shelf protein solution, JTA-004, are designed to offer patients and physicians best-in-class treatment options, superior to existing orthopaedic care.

RANGE OF PRODUCTS

Bone Therapeutics' core technology, ALLOB, is entering Phase IIB clinical development for patients with difficult-to-heal fractures. In addition, the Company is developing an off-the-shelf protein solution, JTA-004, which is entering Phase III development for the treatment of pain in knee osteoarthritis.

CERTIFICATION

Bone Therapeutics' products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio.

CSM - CLINICAL SUPPLIES MANAGEMENT EUROPE SA

Watson & Crick Hill
Rue Granbonpré, n°11
1435 MONT-SAINT-GUIBERT

Tel.: +32 10 23 74 44
Website: www.csmondemand.com

DELEGATE

Stephane PETIT, Director Business Development
Direct Line: +32 10 23 74 35
Mobile: +32 477 47 11 14
E-mail: spetit@csmondemand.com



COMPANY BACKGROUND

CSM, a Clinigen company, is providing innovative clinical trial supplies and biological sample management services since 1997. With two facilities in Post-Brexit EU and three in the US, CSM is committed to ensuring clinical trials are a success, regardless of size or scope.

ADDED VALUE

CSM is structured to offer high flexibility services that are required by Biotech: On-Demand packaging & labelling, secure QP Batch Certification, high reactivity. CSM makes clinical trials more (cost-) efficient and reliable with specialized service solutions like Investigator Initiated Study service, Direct-to-Patient shipping and QP services.

RANGE OF PRODUCTS

Clinical Trial Supplies: Primary and Secondary Packaging & Labeling, Warehousing & Global Distribution, Comparator Drugs & Ancillary Supplies Sourcing, Returns, Reconciliation & Destruction, QP Services, Controlled Drug Services. Biological Sample Management: Biorepository, Biomedical Sample Logistics, Sample Collection Kits, 25 GMP local depots WW, EU Release

MAIN REFERENCES

NO CUSTOMER REFERENCE. It is confidential and not to be disclosed in a conference brochure. Thank you for your understanding.

CERTIFICATION

cGMP Facilities, VAWD (Verified – Accredited Wholesale Distributor), Wholesale Drug Distributor, DEA Registered, Equipment Validated and Calibrated, 21 CFR Part 11 compliant, GDP.

EUROGENTEC

Rue Bois Saint Jean, 5
4102 SERAING

Tel.: +32 4 372 74 00
E-mail: info@eurogentec.com
Website: <https://secure.eurogentec.com/>

DELEGATE

Maria Anna LAURICELLA, Proteomics Business
Development Manager
Direct Line: +32 4 372 76 60
Mobile: +32 473 86 66 75
E-mail : m.a.lauricella@eurogentec.com



COMPANY BACKGROUND

Eurogentec is an ISO 9001, ISO 13485 and FDA inspected CRO/CDMO company based in Belgium offering custom manufacturing of research reagents, molecular and immuno-diagnostic components and injectable GMP biopharmaceutical products for clinical and commercial use.

ADDED VALUE

Eurogentec's Proteomics Division is a leading provider of custom peptides (RUO/GMP), polyclonal and monoclonal antibodies to Life-Science, Diagnostic and Pharmaceutical companies having antibody-related processes, products and services.

RANGE OF PRODUCTS

Large scale polyclonal immunization programs range from our proprietary Speedy 28-day to your custom protocol, from a broad choice of antigen formats, animal species and adjuvants. Monoclonal antibody programs include the production of full-length antibodies in mice via hybridoma development or single-domain (VHH) antibodies developed from llama and expressed recombinantly.

CERTIFICATION

Eurogentec is an ISO 9001, ISO 13485 and FDA inspected CRO/CDMO company. Animal facilities are in compliance with the strictest international animal welfare requirements (FELASA, UK Home Office Animals Scientific Procedure Act.)

IDDI

Avenue Provinciale, 30
1341 OTTIGNIES

Tel.: +32 10 61 44 44
E-mail: info@iddi.com
Website: www.IDDI.com

DELEGATE

Erik FALVEY, Senior Director, Business Development Europe
Direct line: +32 10 62 15 20
Mobile: +33 6 85 86 44 55
E-mail: erik.falvey@iddi.com



COMPANY BACKGROUND

IDDI, founded in 1991, is a service provider of Biostatistical and integrated eClinical services, with a mission to optimize the clinical development of drugs, biologics, biomarkers and devices, using a unique combination of innovative IRT/clinical data management technology and advanced biostatistics.

ADDED VALUE

IDDI combines advanced biostatistics, regulatory and medical expertise, with innovative integrated eClinical solutions to increase efficiency and ensure clinical data readiness for submission.

RANGE OF PRODUCTS

IDDI ensures the successful execution of your clinical development program. Services: Clinical Development Strategy, Trial Design, Integrated EDC-IRT, Data Management, Biostatistics-IDMCs, Biomarker/IVD Validation, CDISC Standardization, Regulatory Support, Therapy-Focused CRO (oncology, ophthalmology), 1100 Phase I-IV Trials, 20 FDA/EMA Approvals, HQ in Belgium - Offices in the US.

MAIN REFERENCES

Supporting 167 clients worldwide (over past 5 years)
80% repeat business

CERTIFICATION

850+ Publications
750+ Scientific Conferences

IMCYSE

Avenue de l'Hôpital, 1
4000 LIEGE
Tel : +32 4 366 47 37
E-mail : info@imcyse.com
Website: www.imcyse.com



DELEGATE

Thomas TAAPKEN, Executive Chairman
Direct line: +32 4 366 47 63
Mobile: +49 17 26 13 20 74
E-mail: t.taapken@imcyse.com

COMPANY BACKGROUND

Imcyse is a clinical-stage biotech company headquartered in Liège, Belgium, created in 2010 as a spin-off of the Catholic University of Leuven (KULeuven). Numerous proof of concept studies have been completed in animal models.

ADDED VALUE

Imcyse technology addresses diseases that represent a huge medical need, in terms of number of diseases and patients, clinical severity and unsatisfactory therapeutic options. There is potential for early treatment and cure of severe chronic diseases, and subsequently to induce regeneration of damaged cells and organs.

RANGE OF PRODUCTS

Imotopes = specific immunotherapeutics for treatment and prevention of auto immune diseases such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and other rare and severe diseases. Potential in allergic diseases and in prevention of immunogenicity.

IMMUNXPERTS SA

Rue Auguste Piccard 48
6041 GOSSELIES

Tel : +32 71 96 01 33
E-mail: info@immunxperts.com
Website: www.immunxperts.com

DELEGATE

Julien ISOARD, Strategic Marketing Advisor
Mobile : +32 483 74 39 04
E-mail: j.isoard@isybio.com

Ellen BOELEN, Business Development Manager Europe
Mobile: +32 472 94 42 62
E-mail: ellen.boelen@immunxperts.com



COMPANY BACKGROUND

Founded in 2014, ImmunXperts provides in vitro services, with a strong focus on immunology. Operating a R&D lab located in Gosselies (Belgium), ImmunXperts collaborates with large pharmaceuticals and small biotechs worldwide.

ADDED VALUE

ImmunXperts acts as a development partner, supporting other organizations in their selection of novel drugs, biotherapeutics and stem cell therapies. The company develops customized in vitro test to provide immunological insights for drug developers.

RANGE OF PRODUCTS

In vitro immunology services to assess the immunogenicity or to characterize the functional potential of drug candidates. But in addition, also in-house banking capabilities and even customized trainings in immunology.

LIEU NETWORK

Passage des Déportés, 2
5030 GEMBLOUX

Tel.: +32 81 62 25 94
E-mail : biotech@reseaulieu.be
Website: <https://www.reseaulieu.be/>

DELEGATE

Virginie BOURGUIGNON, Knowledge Transfer Officer
Direct line: +32 81 72 57 07
Mobile: +32 477 37 57 34
E-mail : virginie.bourguignon@unamur.be



COMPANY BACKGROUND

LIEU is the collaborative network of Knowledge Transfer Offices (KTOs) belonging to the Universities and Higher Education Institutions of the Fédération Wallonie-Bruxelles. LIEU counts around 60 KT advisors connecting business to research and matching the academic offer to the industry needs.

ADDED VALUE

These Business/Research partnership professionals operate as a network within LIEU to provide a one-stop shop for partners. They facilitate the access to a full range of services, skills, state-of-the-art equipment and technology of over 1000 research laboratories and over 10000 academic researchers.

RANGE OF PRODUCTS

The LIEU “Health & Life Sciences Working Group” is the entry point of the network for all the partners in this field and :

- Organizes Business/research events ◊ NETWORK
- Provides relevant information on academic research and facilities ◊ INFORM
- Provides tailored support for businesses in setting up collaborative projects ◊ COOPERATE



POLYPEPTIDE

Chaussée de Tubize, 297
1420 BRAINE-L'ALLEUD

Tel.:+32 2 386 29 86
Website: www.polypeptide.com

DELEGATE
Loïc CORNELISSEN, Sales Manager
E-mail : Loic.cornelissen@polypeptide.com



COMPANY BACKGROUND

Peptide Manufacturing

The PolyPeptide Group - The Ultimate Peptide Partner The PolyPeptide Group is a privately-held group of manufacturing companies which focus on proprietary and generic GMP-grade peptides for the pharmaceutical and biotechnological market. With more than 60 years of experience, the Group is committed to the highest quality of peptide manufacturing, irrespective of whether this is for approved drug substances, GMP peptides in clinical trials, or small-scale non-GMP custom syntheses.

PROMETHERA BIOSCIENCES S.A./N.V.

Watson & Crick Hill
Rue Granbonpré, 11
1435 MONT-SAINT-GUIBERT

Tel : +32 10 39 43 00
E-mail : info@promethera.com
Website : www.promethera.com

DELEGATE

Luc OTTEN, Chief Scientific Officer
Mobile : +32 478 78 10 47
E-mail : luc.otten@promethera.com

Victoria BETOESKI, Global Associate Director
Strategic Planning & Corporate Development
Mobile : +32 470 98 08 99
E-mail : victoria.betoeski@promethera.com



COMPANY BACKGROUND

Promethera® Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The Company has developed its cell therapy technologies by using allogeneic stem and progenitor liver cells. Promethera®'s lead clinical program, derived from its patented cell technology platform HepaStem™, is designed to benefit from its immune-modulatory and anti-fibrotic properties. The Company has strengthened its development portfolio by developing antibody technologies, such as the anti-TNF-R1 antibody Atrosimab to complement its therapeutics options. Promethera®'s team is composed of international experts operating in Belgium, USA, Japan & Switzerland.

ADDED VALUE

- A worldwide company with a local presence in 4 countries.
- A unique set of technological assets to bring life-saving treatments to reduce the need for liver transplantation.
- Largest liver sourcing and unique supply chain on a global basis.
- Robust investor consortium.

RANGE OF PRODUCTS

Cell Therapies:

- HepaStem™ for ACLF (IM) in Phase 2B
- HepaStem™ for NASH/Fibrosis starting Phase 2A
- H2Stem® for Tissue Repair in Pre-Clinical phase

Biologicals:

- Atrosimab for NASH/Fibrosis in Pre-Clinical Phase

SALAMANDERU

Rue de la Source, 191C
5351 HAILLOT

Tel.: +32 2 234 50 46
E-mail: jessica@salamanderu.com
Website : www.salamanderu.com

DELEGATE

Claude DEDRY, CEO
Mobile : +32 476 23 93 13
E-mail : claudio@salamanderu.com

Tony DONOLATO, COO
Mobile : +32 476 79 88 53
E-mail : tony@salamanderu.com



COMPANY BACKGROUND

SalamanderU is a technology company made of a multidisciplinary team of business experts in life science industry, pharmaceutical engineering and IT.

ADDED VALUE

These solutions are major levers for your operational performance needs

We accompany you by integrating tailor-made innovative solutions

This accompaniment is carried out on the complete cycle of the project, from the definition of your need to the regulatory accreditation.

RANGE OF PRODUCTS

Technic solution to support you need of containment, in particular with our acrylic resin isolator that encompasses all your equipment. Digital solution with our voice-driven eBR (SMARTREG), patented number 1 in the world and our Remote-control software (IP-Cprotect) including an eBR, EMS and data collect of the manufacturing process data. The whole can be deployed in the form of an integrated unit (Smart Unit) with a package of consulting services.

MAIN REFERENCES

Example of our Smart Unit fully deployed, up and running and inspected by AFMPS with RevaTis, PDCLine & Volition SmartReg available in the cloud, CER laboratory animal house infrastructure.

CERTIFICATION

Our solution SmartReg is GAMP4, 21CFR Part 11

SAMBREINVEST

Avenue Georges Lemaître, 62
Aéropôle
6041 GOSELIES

Tel.: + 32 71 25 94 94
E-mail: sambrinvest@sambrinvest.be
Website: www.sambrinvest.be

DELEGATE
Helena POZIOS, Investment Manager
Mobile: +32 493 19 59 40
E-mail: helena.pozios@sambrinvest.be



COMPANY BACKGROUND

Sambrinvest is an actor in risk capital in the region of Charleroi in Belgium, based in the aeropole of Gosselies, with the objective to support the development of SMEs. Thanks to its expertise, it advises entrepreneurs at every development stage of their projects whilst respecting their management autonomy.

Sambrinvest is active into three main activities which are: Biotechnology, Digital and traditional activities.

ADDED VALUE

Sambrinvest is active in the biotech and medtech sector. We have a strong expertise and a large network as we had financed companies since more than 30 years in the region and we had financed venture capital fund.

RANGE OF PRODUCTS

Sambrinvest provides equity, quasi-equity and loans to support the development of SMEs.

MAIN REFERENCES

Sambrinvest is active in almost all Biotech companies located in the BioPark Dev. in Gosselies. Sambrinvest is the financial sponsor of Bone Therapeutics, Inhatarget, Antigon, Tools4Patient, Minoryx, NCardia etc. Sambrinvest has also financed some capital funds specialized in Biotechnology such as Theodorus, Innovation Fund, Fund+, Newton, etc.

SECOYA TECHNOLOGIES

Fond des Més 4
1348 LOUVAIN-LA-NEUVE

Tel : +32 10 45 64 99
E-mail : info@secoya-tech.com
Website: www.secoya-tech.com

DELEGATE

Olivier ANDRE, General Manager/BD
Mobile : +32 475 51 19 17
E-mail : olivier.andre@secoya-tech.com



COMPANY BACKGROUND

Secoya Technologies develops and supplies novel technologies for the production of ingredients with unique quality properties by tailoring industrial process equipment down to the ideal scale for an optimal control. Our technologies are inherently compatible with continuous manufacturing

ADDED VALUE

Secoya technologies enable our customers to manufacture products with very well-defined properties, high production efficiency and consistency. Based on flow process, the footprint of Secoya equipment is about the square meter reducing capital investment and operating costs.

RANGE OF PRODUCTS

Micro-Encapsulation: Reliably production of monodisperse micro-particles with all types of encapsulated active ingredients and matrix materials.

Crystallisation technology: A one step production technology of well-defined crystals


Pervaporation: Facile removal/addition of a volatile component from/to a solution at low temperature.

SPECTRALYS BIOTECH

Rue Auguste Piccard, 48
6041 GOSSELIES

E-mail : info@spectralysbiotech.com
Website : www.spectralysbiotech.com

DELEGATE
Allison DERENNE, General Manager
Mobile : +32 497 05 67 08
E-mail : allison.derenne@spectralysbiotech.com



COMPANY BACKGROUND

Spectralys Biotech offers analytical services for biomolecules (especially proteins) based on FTIR spectroscopy.

ADDED VALUE

Using our sharp expertise, we can assess 4 critical quality attributes: structure, glycosylation, total protein concentration and the quantification of excipients such as Tween.

RANGE OF PRODUCTS

Key applications include: multi-parametric batch-to-batch consistency; stability and stress studies; comparability studies for biosimilar candidates; structural characterization and in-process analytical tool.

SYNGULON

Rue du Bois Saint-Jean 15/1
4102 SERAING

Tel : +32 4 290 55 45
E-mail : contact@syngulon.com
Website : www.syngulon.com

DELEGATE
Guy HELIN, CEO



COMPANY BACKGROUND

Syngulon introduces a new genetic technology (US Patent 9,333,227 / 10,188,114) focusing on the control of microorganisms for recombinant products to solve:

1. Genetic drift
2. Genetic stability
3. Yield increase
4. Ease of use
5. Antibiotic-free selection of expressing clones

ADDED VALUE

The issued patents US Patent 9,333,227 / 10,188,114 are based on the use of bacteriocin/immunity.

They are part of a new worldwide patent portfolio developed by Syngulon and available for licensing in all fields of use on a non-exclusive base.

UNIVERSITÉ LIBRE DE BRUXELLES

Avenue Franklin D. Roosevelt, 50
1050 BRUSSELS

Tel.: +32 2 650 47 22
E-mail: ulbtto@ulb.be
Website: www.ulbtto.be

DELEGATE

Joachim RUOL, Business Developer
Direct Line: +32 2 650 30 67
Mobile: +32 475 64 18 91
E-mail: joachim.ruol@ulb.be



COMPANY BACKGROUND

Université libre de Bruxelles is a comprehensive University active in all domains of the Life Sciences and Pharma. Its academic hospital is involved in numerous clinical studies in line with translational research performed by academic researchers. ULB also benefits from a multidisciplinary team of Technology Transfer Officers in order to support all types of interactions between researchers and industrial partners.

ADDED VALUE

The University is at the forefront of frontier research and provides industrial partners with expertise and access to technology platforms in order to advance their research and development activities. In addition, patented technologies developed within the University are available for licensing and/or collaborative research in order to bring such academic innovation onto the market.

RANGE OF PRODUCTS

A portfolio of IP assets (patent applications as well as proprietary software and biological material) is available for licensing at the University. Technological platforms benefiting from state-of-the-art equipment and scientific expertise, such as the Center for Microscopy and Molecular Imaging (CMMI) or the Analytical platform of the Faculty of Pharmacy, also provide services to industrial partners in the Life Sciences and Pharma sectors.

MAIN REFERENCES

WO2016001447 (A1) - METHOD AND SYSTEM FOR THE PRODUCTION OF RECOMBINANT PROTEINS BY CELLS

WO2016102541 (A1) - COMPOSITION COMPRISING VANCOMYCIN AND ORLISTAT

CERTIFICATION

With its HR Excellence in Research award, ULB is mindful of its researchers' opportunities for international exchanges, as well as of their training and career development

UNIVERCELLS S.A.

Rue Auguste Piccard, 48
6041 GOSSELIES

Tel.: +32 2 318 83 48
Website: www.univercells.com

DELEGATE
Thomas THEELEN, Business Development Manager
t.theelen@univercells.com

Igor OLEWIECKI, Sales Manager
i.olewiecki@univercells.com



COMPANY BACKGROUND

Univercells focuses on increasing the availability of affordable biologics to address global health challenges. To achieve this, the company develops cost-effective manufacturing solutions for vaccines, gene therapies and biotherapeutics.


Our proprietary core technologies and continuous process intensification approach achieves production with a smaller footprint and significantly lower overall capital and operational costs. Our scale-X™ single-use fixed-bed bioreactor scales up to 600m² and our NevoLine™ intensified and integrated manufacturing platform provides large-scale capacity with low costs. Both are commercially available for third party use.

WBC VENTURES

Avenue de l'Hôpital, 1-11
4000 LIEGE

Tel.: +32 4 246 51 10
E-mail : info@wbc.ventures
Website : www.wbc.ventures

DELEGATE
Serge PAMPFER, CEO
Mobile : +32 479 33 08 63
E-mail : pampfer@wbc.ventures



COMPANY BACKGROUND

WBC VENTURES is the new iteration of BIOTECH COACHING SA, a private company created in 2006 to incubate and finance life sciences start-ups in Belgium. Our focus is now on accelerating scaling-up companies toward their industrialization and commercialization.

ADDED VALUE

WBC VENTURES clients are mostly biotech and medtech companies facing the many challenges of accessing the European healthcare market. Our deep knowledge of the key industry players and leverages as well as our extensive network of experts and managers enables us to help our clients design and execute effective clinical development and market access strategies.

RANGE OF PRODUCTS

WBC VENTURES methodology always starts with an « Internationalization Readiness Level » test that allows us to offer a tailored approach to each client. Our guidance then spans the entire product life cycle going forward, including recommendations in regulatory and compliance issues, clinical trials and pharmacovigilance, management of human and investment resources.

MAIN REFERENCES


All the life sciences companies that have been incubated by WBC VENTURES now form a tight network of potential partners, together with the BLOWIN cluster and the AWEX agency.

Feel inspired



Laurent Mercenier, L'Oréal

« In Wallonia, we have found skillful human resources and an ideal location »



Wallonia.be

Wallonia is full of great assets. Help spread the word !

You like Wallonia and you want to enhance its global reputation ? Join our network of Wallonia.be Brand Ambassadors !

One mission, lots of benefits!

We want to promote Wallonia and you can help us: share information from our website and social networks, add the Wallonia.be logo and slogan Feel inspired to your website, blog or email signature, inform us about development opportunities for the Wallonia Region, bring the brand to life by actively taking part in conversations on Facebook, Twitter or LinkedIn and by recruiting other Ambassadors...

In return, you get a chance to:


- promote your activities and share your success stories on the Wallonia.be Ambassadors' blog
- expand your network using the private area on the portal
- receive a newsletter about the Region and the Brand Ambassadors' network
- be invited to exclusive events
- use the Wallonia brand logo and benefit from the Region's reputation

How to become a Brand Ambassador?

Complete the online application form on the website (<http://www.wallonia.be/en/ambassadors>). Simply answer three questions and we will let you know if your profile matches the network we want to implement.


Do you want more information?

Contact : ambassador@wallonia.be !



Wallonia is open to the world !

... with a sense of sharing, accessibility, technical know-how and quality of life



Wallonia.be

EXPORT
INVESTMENT

WALLONIA EXPORT-INVESTMENT AGENCY

Export

Place Saintelette 2
B - 1080 BRUSSELS
BELGIUM
Tel.: +32 2 421 82 11
E-mail: mail@awex.be
Website: www.wallonia-export.be

Investment

Avenue des Dessus de Lives 6
B - 5101 NAMUR
BELGIUM
Tel.: +32 81 33 28 50
E-mail: welcome@investinwallonia.be
Website: www.investinwallonia.be



Wallonia.be

Feel inspired

